**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 11356**

**Columns:** **RESEARCH REPORT**

***Clostridium difficile* infection aggravates colitis in interleukin 10-deficient mice**

Kim MN *et al.* *C. difficile* infection aggravates colitis

Mi Na Kim, Seong-Joon Koh, Jung Mogg Kim, Jong Pil Im, Hyun Chae Jung, Joo Sung Kim

**Mi Na Kim,** Seoul National University Healthcare System Gangnam Center, Seoul National University Hospital, Seoul 135-984, South Korea

**Seong-Joon Koh,** Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul National University College of Medicine, Seoul 157-707, South Korea

**Jong Pil Im, Hyun Chae Jung, Joo Sung Kim,** Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul 110-744, South Korea

**Jung Mogg Kim,** Department of Microbiology, Hanyang University College of Medicine, Seoul 133-792, South Korea

**Author contributions:** Kim MN and Kim JS conceived of and designed the study, and wrote the paper; Kim MN and Koh SJ performed the experiments; Kim MN, Kim JM, Im JP, Jung HC and Kim JS analyzed the data; all authors read and approved the final version of the paper.

**Correspondence to: Joo Sung Kim, MD, PhD,** Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Chongno-gu, Seoul 110-744, South Korea. jooskim@snu.ac.kr

**Telephone:** +82-2-7408112 **Fax:** +82-2-7436701

**Received**: May 17, 2014 **Revised:** June 27, 2014

**Accepted:** July 29, 2014

**Published online:**

**Abstract**

**AIM:** To investigate the effect of *Clostridium difficile* (*C. difficile*) infection in an interleukin 10-deficient (IL-10-/-) mouse model of inflammatory bowel disease.

**METHODS:** Bone marrow-derived dendritic cells (BMDCs) isolated from wild type (WT) and IL-10-/-mice were stimulated for 4 h with *C. difficile* toxin A (200 μg/mL), and gene expression of interferon (IFN)-γ, interleukin (IL)-12 and IL-23 was determined by real-time reverse transcription polymerase chain reaction. WT and IL-10-/- mice (*n* = 20 each) were exposed to an antibiotic cocktail for three days and then were injected with clindamycin (i.p.). Mice (*n* = 10 WT, 10 IL-10-/-) were then challenged with oral administration of *C. difficile* (1 × 105 colony forming units of strain VPI 10463). Animals were monitored daily for 7 d for signs of colitis. Colonic tissue samples were evaluated for cytokine gene expression and histopathologic analysis.

**RESULTS:** *C. difficile* toxin A treatment induced IFN-γ gene expression to a level that was significantly higher in BDMCs from IL-10-/- compared to those from WT mice (*P <* 0.05). However, expression of IL-12 and IL-23 was not different among the groups. Following *C. difficile* administration, mice developed diarrhea and lost weight within 2-3 d. Weight loss was significantly greater in IL-10-/- compared to WT mice (*P <* 0.05). *C. difficile* infection induced histopathologic features typical of colitis in both IL-10-/- and WT mice. The histopathologic severity score was significantly higher in the IL-10-/- than in WT mice (mean ± standard error; 5.50 ± 0.53 *vs* 2.44 ± 0.46; *P <* 0.05). This was accompanied by a significantly greater increase in IFN-γ gene expression in colonic tissues from IL-10-/- than from WT mice challenged with *C. difficile* (*P <* 0.05).

**CONCLUSION:** These results indicate that colitis is more severe after *C. difficile* infection in IL-10-/-mice, and that IFN-γ expression is involved in this process.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** *Clostridium difficile*; Inflammatory bowel disease; Interleukin 10-deficient mice; Interferon-γ; Colitis

**Core tip:** The results of this study indicate that *Clostridium difficile (C. difficile)* infection induces more severe colitis in the interleukin 10-deficient (IL-10-/-) mouse model of inflammatory bowel disease (IBD). Moreover, induction of interferon-γ gene expression was greater in the IL-10-/- mice and their bone marrow-derived dendritic cells compared to wild type mice following *C. difficile* infection and exposure to *C. difficile* toxin A, respectively. This study demonstrates the establishment of *C. difficile*-aggravated colitis in an IBD animal model, which provides a useful tool for studying the relationship between *C. difficile* and host immune response of the gut in IBD.

Kim MN, Koh SJ, Kim JM, Im JP, Jung HC, Kim JS. *Clostridium difficile* infection aggravates colitis in interleukin 10-deficient mice. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a complex chronic inflammatory gastrointestinal disorder of unknown cause in genetically predisposed hosts[[1](#_ENREF_1)]. There is accumulating evidence concerning the importance of intestinal microbiota in the pathogenesis of IBD, including recent culture-dependent and –independent analyses showing that patients with IBD have dysbiosis characterized by a less complex profile of commensal bacteria and a higher number of pathogenic bacteria[[2](#_ENREF_2)].

*Clostridium difficile (C. difficile)* is a gram-positive, anaerobic, spore-forming bacillus. *C. difficile* infection (CDI) is the most common cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis[[3](#_ENREF_3),[4](#_ENREF_4)]. Disease-causing toxins released by the bacteria, toxins A and B, act directly on intestinal epithelial cells, leading to chemokine release, cell rounding and apoptosis or necrosis, resulting in inflammation and intestinal damage[[5](#_ENREF_5),[6](#_ENREF_6)]. These toxins are glucosyltransferases that irreversibly inactivate Rho proteins, leading to the disruption of the cytoskeleton and tight junctions and subsequent cell death, and concurrently induce the release of interleukin (IL)-8 and intracellular adhesion molecule-1 from intestinal epithelial cells, which further leads to neutrophil adhesion, infiltration, and mucosal inflammation. Moreover, the toxins may activate immune cells and neurons once the intestinal epithelial barrier is disrupted[[7](#_ENREF_7)].

IBD is recognized as a risk factor for CDI, and a high prevalence of CDI is observed in pediatric patients with both active and inactive Crohn’s disease and ulcerative colitis[[8](#_ENREF_8)]. *C. difficile* affects the course of IBD in several ways, including triggering disease flares, sustaining activity, and in some cases, acting as a ”silent partner”. Moreover, CDI is associated with a longer hospital stay and a higher morbidity and mortality in patients with IBD[[9](#_ENREF_9),[10](#_ENREF_10)]. Because *C. difficile* colitis can both mimic and precipitate an IBD flare, it is essential that clinicians are vigilant in identifying and addressing this infection[[11](#_ENREF_11)].

*C*. *difficile-*associated disease has been studied in many animal species, including hamsters, guinea pigs, rabbits, and germ-free mice and rats. Although hamsters have been used to investigate the pathogenesis and treatment of *C. difficile* colitis, they have limitations in developing fulminant and lethal cecitis[[12](#_ENREF_12)]. In recent years, mouse models of intestinal inflammation based on bacterial infections have been used to study the roles of individual bacterial species and specific bacterial components in the pathogenesis of IBD[[13](#_ENREF_13)]. Although a recently established mouse model of *C. difficile*-associated disease closely resembles the human disease[[14](#_ENREF_14)], there are no established models to study the mechanism of CDI-induced intestinal inflammation in IBD or the pathogenic role of *C. difficile* in mucosal immune dysregulation. In the present study, control and IL-10-deficient (IL-10-/-) mice were used to examine *C. difficile* toxin A-activated bone marrow-derived dendritic cells (BMDCs) and the effect of CDI on intestinal inflammation.

**MATERIALS AND METHODS**

***Mice***

Seven-week-old specific pathogen-free male C57BL/6 wild type (WT) and IL-10-/- mice used for the experiments were supplied by the Center for Animal Resource and Development (Seoul, South Korea). Mice were maintained in a controlled laboratory environment at 24 ± 2°C and 50 ± 5% humidity under a 12/12 h (light/dark) cycle. Mice were given *ad libitum* access to irradiated mouse feed (Purina Korea, Seoul, Korea) and 2 ppm chloride-supplemented reverse osmosis water. To prevent mice from eating their feces, a grid floor through which fecal matter could pass was installed during the rearing period. All procedures were approved by the Institutional Animal Care and Use Committee at Seoul National University (IACUC No.SNU-100318). The experiments were conducted in accordance with the August 2010 revision of The Guiding Principles for the Care and Use of Laboratory Animals (American Physiological Society).

***Generation and culture of BMDCs***

BMDCs were generated from the femurs of WT and IL-10-/- mice as previously described[[15](#_ENREF_15)]. Bone marrow cells were cultured in complete media (RPMI-1640) supplemented with 10 ng/mL of murine recombinant granulocyte-macrophage colony-stimulating factor and 10 ng/mL of murine recombinant IL-4 (Peprotech, Rocky Hill, NJ, United States). The culture medium was changed after three days, and again after five days, of culture. On the seventh day of culture, non-adherent cells were collected as BMDCs. Flow cytometric analysis indicated that > 93% of the collected cells were CD11c+ and CD11b+ (BD Pharmingen, San Diego, CA, United States)[[16](#_ENREF_16)].

***Real time reverse transcription-polymerase chain reaction (RT-PCR)***

After stimulating BMDCs for 4 h with 200 μg/mL of *C. difficile* toxin A (Sigma-Aldrich, St. Louis, MO, United States), total RNA was extracted with Trizol (Invitrogen of Thermo Fisher Scientific Inc., Waltham, MA, USA) and reverse transcribed. Amplification was performed with SYBR Green PCR Master Mix on an ABI Prism 7000 Sequence Detection System (Applied Biosystems of Thermo Fisher Scientific Inc.) using primers for interferon (IFN)-γ, IL-12p40, and IL-23p19 (Table 1). Reactions were performed in triplicate, and the data were normalized to β-actin.

***C. difficile culture***

*C. difficile* strain VPI 10463 (ATCC 43255; American Type Tissue Culture Collection, Manassas, VA, United States) was used in the present study. Before oral administration to mice, the frozen strain was thawed and cultured in brain heart infusion-supplemented media at 37°C for three days under anaerobic conditions.

***Establishment of a C. difficile colitis model in IL-10-/- mice and experimental grouping***

WT and IL-10-/- mice were randomly assigned to either a control group (*n* = 10 each) or a *C. difficile* group (*n* = 10 each) and fed irradiated mouse feed mixed with an antibiotic cocktail (40 mg/kg kanamycin, 3.5 mg/kg gentamicin, 4.2 mg/kg colistin, 21.5 mg/kg metronidazole, and 4.5 mg/kg vancomycin) for three days. One day after the last antibiotic cocktail, the mice were injected with clindamycin (10 mg/kg, i.p.), and WT and IL-10-/- mice in the *C. difficile* groups received oral administration of 1 × 105 colony forming units of *C. difficile* the next day (Figure 1). All mice were monitored daily for signs of colitis (*e.g.,* diarrhea, hunched posture, wet tail, and weight loss[[14](#_ENREF_14)]) and euthanized seven days later.

***Histopathologic assessment of colonic tissue***

Colonic tissues were extracted from euthanized mice and either fixed in 10% buffered formalin, embedded in paraffin and stained with hematoxylin-eosin or frozen in liquid nitrogen to quantify biochemical parameters. Histopathologic examination was performed on the proximal and distal colon of each animal by an independent pathologist who was blinded to the study methods, using previously reported classification standards[[17](#_ENREF_17)]. Briefly, each of three factors was scored on a scale of 0 to 3 (none, mild, moderate, or severe, respectively), including neutrophil influx into tissues, colonic mucosal edema, and epithelial cell injury. The overall score was the sum of each component score. The severity of colitis was quantified by the total score.

***Statistical analysis***

Statistical analysis was performed using the SPSS version 19.0 statistical software (IBM, Armonk, NY, United States). Groups were compared using the Mann-Whitney *U*-test. All data are expressed as the mean ± standard error. *P <* 0.05 was considered to indicate statistical significance.

**RESULTS**

***Cytokine gene expression in BMDCs after stimulation with C. difficile toxin A***

Treatment with *C. difficile* toxin A significantly increased the expression of IFN-γ in BDMCs extracted from IL-10-/- mice (*P* < 0.05 *vs* WT) (Figure 2). In contrast, treatment did not affect the expression of IL-12 or IL-23 in BDMCs from WT or IL-10-/- mice.

***C. difficile-induced weight loss***

There was no difference in baseline body weights between the WT and IL-10-/- mice. *C. difficile* exposure resulted in weight loss within 2-3 d after administration (Figure 3). Weight loss was greater in the IL-10-/- than in the WT mice (*P* = 0.01), with 15% weight loss in the IL-10-/- mice by the fourth day compared to 7% loss in WT mice infected with *C. difficile* by the third day. The mice recovered their weight loss by the seventh day after *C. difficile* administration.

***Histopathologic features of C. difficile-induced colitis***

On gross examination, mice with *C. difficile*-induced colitis exhibited shortened colons and colonic mucosal edema. Microscopic observation confirmed the presence of desquamate or necrotic epithelial cells as well as extensive mucosal and submucosal edema, and an influx of inflammatory cells (Figure 4). Histopathologic severity scores for the controls were 0.37 ± 0.1 and 0.45 ± 0.21 for the WT and IL10-/- groups, respectively. Challenge with *C. difficile* significantly increased the scores in both groups (*P*s < 0.05). Moreover, the severity of *C. difficile*–induced colitis was significantly greater in IL10-/- mice compared with WT (5.50 ± 0.53 *vs* 2.44 ± 0.46; *P* < 0.05).

***Cytokine gene expression in mice with C. difficile colitis***

*C. difficile* challenge induced an increase in IFN-γ mRNA that was ten-fold in WT mice, and significantly higher (> 100-fold) in IL-10-/- mice (*P* < 0.05 *vs* WT) (Figure 5). In addition, there was a ten-fold increase in IL-12 expression for both WT and IL-10-/- mice with *C. difficile* challenge, but not significant compared to non-challenge group. In contrast, there were no strain or treatment effects observed for the IL-23 mRNA expression.

**DISCUSSION**

Recent studies provide convincing evidence that intestinal microbiota play a critical role in the pathogenesis of IBD[[2](#_ENREF_2),[18](#_ENREF_18)], and germ-free and gnotobiotic techniques have demonstrated that they are necessary for the development of intestinal inflammation[[19](#_ENREF_19),[20](#_ENREF_20)]. Mouse models of gut inflammation induced by bacteria such as *Citrobacter rodentium, Salmonella enterica, Bacteroides fragilis* and *Campylobacter* sp. have been reported, which provide mechanisms for bacteria-associated gastroenteritis[[13](#_ENREF_13)]. Although animal models of *Clostridium*-associated disease have been reported, there are no established models to study the mechanism of *Clostridium*-aggravated intestinal inflammation in IBD. The results of the present study confirm that CDI causes acute colitis within three days, and demonstrate that this was significantly more severe in a mouse model of IBD.

 Various mouse models have been used to investigate IBD, the majority of which are based either on chemical induction (with dextran sodium sulfate or 2,4,6-trinitrobenzenesulfonic acid), immune cell transfer, or gene targeting. Mice deficient in IL-10 spontaneously develop IBD that progresses over several months, characterized by increased inflammatory cytokine production[[21](#_ENREF_21),[22](#_ENREF_22)]. These mice rapidly develop severe, chronic IBD after treatment with piroxicam, a non-steroidal anti-inflammatory drug, as endogenous prostaglandins are important inhibitors of the development of intestinal inflammation[[23](#_ENREF_23)]. We therefore hypothesized that CDI would have a similar effect on these mice. We observed a development of acute colitis from CDI that was amplified in IL-10-/- mice. Moreover, CDI resulted in histopathologic features typical of *C. difficile* colitis in humans, such as epithelial cell damage, inflammatory cells infiltration, and submucosal edema. To the best of our knowledge, this is the first animal model of established *C. difficile*-aggravated colitis in IBD, which provides a useful tool for studying the relationship between *C. difficile* and host immune responses of the gut in IBD. As CDI has emerged as a significant clinical challenge for IBD patients, the establishment of a novel relevant model will enhance our understanding of the mechanisms involved, and precipitate the development of future therapies.

 Cytokines play a central role in the development and control of intestinal inflammation, particularly IL-12 and IL-23, which share the p40 subunit[[24](#_ENREF_24)]. A pathogenic role for IL-23 signaling in CDI has been recently reported in both human and murine models[[25](#_ENREF_25)]. Both IL-23 and IL-12 have been demonstrated as more important than IFN-γ for inducing chronic inflammation in IL-10-/- mice[[26](#_ENREF_26),[27](#_ENREF_27)]. However, in the present study, we observed a more dramatic increase in IFN-γ expression in the colonic tissues of IL-10-/- mice infected with *C. difficile.* Nonetheless, these results are consistent with a previous report in which IFN-γ played a decisive role in *C. difficile* toxin A-mediated enteritis through acute inflammatory reaction with neutrophil infiltration[[28](#_ENREF_28)]. Indeed, results from the *in vitro* analysis in the present study confirmed that *C. difficile* toxin A induces IFN-γ expression in BMDCs. IFN-γ triggers the secretion of pro-inflammatory mediators by activated macrophages, and regulates the expression of adhesion molecules[[29](#_ENREF_29),[30](#_ENREF_30)]. IFN-γ also increases the permeability of intestinal epithelial cells[[31-33](#_ENREF_31)], which can occur via widening of the tight junctions, without triggering necrosis[[34](#_ENREF_34)]. IFN-γ activation may be associated with the aggravation of colitis in IL-10-/- mice infected with *C. difficile*, as a greater increase in IFN-γ expression was observed in these mice. It is plausible that an acute inflammatory reaction such as heavy neutrophil infiltration was induced by CDI infection in the IL-10-/- mice that is distinct from the chronic inflammatory reaction in colitis.

 Dendritic cells play a critical role in the pathogenesis of IBD due to the link between innate and adaptive immunity[[35](#_ENREF_35),[36](#_ENREF_36)]. A recent paper demonstrated that surface layer proteins from *C. difficile* induce inflammatory and regulatory cytokines (IL-1β and IL-6) in human monocytes and dendritic cells[[37](#_ENREF_37)]. In addition, it has been reported that *C. difficile* toxin A promotes dendritic cell maturation through p38 mitogen-activated protein kinase, an inhibitor of IκB, and the NF-κB signaling pathway[[38](#_ENREF_38)]. In the present study, we show that toxin A increased the expression of IFN-γ in BMDCs. However, further studies are needed to explore the specific mechanisms of IFN-γ activation in dendritic cells by *C. difficile* toxin A.

The present study presents a model of CDI-aggravated colitis, which provides an additional platform for evaluation of other substances that can exacerbate colitis. For example, some pre- and probiotics, advocated for their potential benefits in IBD, pouchitis and diarrhea, do not alleviate all symptoms. Intestinal inflammation was not reduced with *Lactobacillus fermentum* BR11 and fructo-oligosaccharide in an experimental model of colitis[[39](#_ENREF_39)]. However, administration of a cocktail consisting of six bacterial strains, including *Anaerostipes* sp., has been shown to relieve chronic CDI in mice[[40](#_ENREF_40)]. In another study, *Lactobacillus acidophilus* was shown to modulate the virulence of *C. difficile*[[41](#_ENREF_41)].

In conclusion, the results of this study indicate that CDI induces more severe acute colitis in the IL-10-/- model of chronic IBD. Moreover, this exacerbation likely involves IFN-γ, as expression of this cytokine was dramatically enhanced. Use of this novel mouse model will allow further investigation into mechanisms associated with CDI-induced aggravation of intestinal inflammation in IBD and the pathogenic role of *C. difficile* in mucosal immune dysregulation.

**COMMENTS**

***Background***

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a complex chronic inflammatory gastrointestinal disorder of unknown cause in a genetically predisposed host. There is accumulating evidence concerning the importance of microbiota in the pathogenesis of IBD, and infection with *Clostridium difficile* is associated with a higher morbidity and mortality in IBD patients. However, the pathogenic role of *C. difficile* is still unknown.

***Research frontiers***

Although animal models of *C. difficile*-associated disease have been reported, there are no established models to study the mechanism of *C. difficile*-aggravated intestinal inflammation in IBD. This study demonstrates *C. difficile* infection in a model of spontaneous, chronic IBD, for the purpose of exploring mechanisms of intestinal inflammation.

***Innovations and breakthroughs***

Although previous mouse models of *C. difficile*-associated disease closely resemble the human disease, there are no animal models of *C. difficile*-aggravated IBD-like colitis. The present study utilizes interleukin 10-deficient (IL-10-/-) mice, which express a spontaneous, chronic form of IBD, and investigates the effect and mechanism of *C. difficile*-induced colitis. *In vitro* and *in vivo* experiments implicate the involvement of interferon (IFN)-γ in this process. Furthermore, the results establish a model of *C. difficile*-aggravated intestinal inflammation in IBD.

***Applications***

This study establishes an animal model of *C. difficile*-aggravated colitis in IBD, which provides a useful tool for studying the relationship between *C. difficile* infection and host immune response within IBD-affected intestinal mucosa.

***Terminology***

IL-10 is a cytokine with potent anti-inflammatory activity. IL-10-/- mice develop a spontaneous, chronic IBD-like colitis that can take months to develop. IFN-γ is a cytokine important for innate and adaptive immune response to infection. IL-12 and IL-23 are inflammatory cytokines important for the differentiation of T-cells.

***Peer review***

The authors examined the effect of *C. difficile* toxin A on cytokine expression in bone marrow-derived dendritic cells (BMDCs) and *C. difficile* infection on intestinal inflammation in IL-10-/- mice. Toxin A and *C. difficile* infection significantly induced IFN-γ gene expression in BMDCs and colonic tissues of the IL-10-/- mice. In addition, the IL-10-/- mice developed more severe colitis following *C. difficile* infection, compared to wild type mice. These results establish a model of *C. difficile*-aggravated IBD-like colitis, and suggest a role for IFN-γ in this process.

**REFERENCES**

1 **Xavier RJ**, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; **448**: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]

2 **Chassaing B**, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]

3 **Bartlett JG**, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. *N Engl J Med* 1978; **298**: 531-534 [PMID: 625309 DOI: 10.1056/nejm197803092981003]

4 **Kyne L**, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. *Clin Infect Dis* 2002; **34**: 346-353 [PMID: 11774082 DOI: 10.1086/338260]

5 **Kelly CP**, LaMont JT. Clostridium difficile infection. *Annu Rev Med* 1998; **49**: 375-390 [PMID: 9509270 DOI: 10.1146/annurev.med.49.1.375]

6 **Kelly CP**, Pothoulakis C, LaMont JT. Clostridium difficile colitis. *N Engl J Med* 1994; **330**: 257-262 [PMID: 8043060 DOI: 10.1056/nejm199401273300406]

7 **Sun X**, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. *Toxins* (Basel) 2010; **2**: 1848-1880 [PMID: 22069662 DOI: 10.3390/toxins2071848]

8 **Mann EA**, Saeed SA. Gastrointestinal infection as a trigger for inflammatory bowel disease. *Curr Opin Gastroenterol* 2012; **28**: 24-29 [PMID: 22080823 DOI: 10.1097/MOG.0b013e32834c453e]

9 **Ananthakrishnan AN**, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut* 2008; **57**: 205-210 [PMID: 17905821 DOI: 10.1136/gut.2007.128231]

10 **Navaneethan U**, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. *World J Gastroenterol* 2010; **16**: 4892-4904 [PMID: 20954275]

11 **Issa M**, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. *Inflamm Bowel Dis* 2008; **14**: 1432-1442 [PMID: 18484669 DOI: 10.1002/ibd.20500]

12 **Fekety R**, Silva J, Toshniwal R, Allo M, Armstrong J, Browne R, Ebright J, Rifkin G. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. *Rev Infect Dis* 1979; **1**: 386-397 [PMID: 549190]

13 **Nell S**, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. *Nat Rev Microbiol* 2010; **8**: 564-577 [PMID: 20622892 DOI: 10.1038/nrmicro2403]

14 **Chen X**, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of Clostridium difficile-associated disease. *Gastroenterology* 2008; **135**: 1984-1992 [PMID: 18848941 DOI: 10.1053/j.gastro.2008.09.002]

15 **Kang SJ**, Kim JM, Koh SJ, Kim SH, Im JP, Jung HC, Kim JS. The guggulsterone derivative GG-52 inhibits NF-κB signaling in bone marrow-derived dendritic cells and attenuates colitis in IL-10 knockout mice. *Life Sci* 2013; **92**: 1064-1071 [PMID: 23603141 DOI: 10.1016/j.lfs.2013.04.003]

16 **Kim JS**, Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. *Immunology* 2005; **115**: 375-387 [PMID: 15946255 DOI: 10.1111/j.1365-2567.2005.02156.x]

17 **Kelly CP**, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. *J Clin Invest* 1994; **93**: 1257-1265 [PMID: 7907603 DOI: 10.1172/jci117080]

18 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

19 **Uhlig HH**, Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. *Eur J Immunol* 2009; **39**: 2021-2026 [PMID: 19672896 DOI: 10.1002/eji.200939602]

20 **Sellon RK**, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun* 1998; **66**: 5224-5231 [PMID: 9784526]

21 **Berg DJ**, Davidson N, Kühn R, Müller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. *J Clin Invest* 1996; **98**: 1010-1020 [PMID: 8770874 DOI: 10.1172/jci118861]

22 **Kühn R**, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 1993; **75**: 263-274 [PMID: 8402911]

23 **Berg DJ**, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid development of colitis in NSAID-treated IL-10-deficient mice. *Gastroenterology* 2002; **123**: 1527-1542 [PMID: 12404228]

24 **Strober W**, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]

25 **Buonomo EL**, Madan R, Pramoonjago P, Li L, Okusa MD, Petri WA. Role of interleukin 23 signaling in Clostridium difficile colitis. *J Infect Dis* 2013; **208**: 917-920 [PMID: 23776194 DOI: 10.1093/infdis/jit277]

26 **Davidson NJ**, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. *J Immunol* 1998; **161**: 3143-3149 [PMID: 9743382]

27 **Yen D**, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *J Clin Invest* 2006; **116**: 1310-1316 [PMID: 16670770 DOI: 10.1172/jci21404]

28 **Ishida Y**, Maegawa T, Kondo T, Kimura A, Iwakura Y, Nakamura S, Mukaida N. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. *J Immunol* 2004; **172**: 3018-3025 [PMID: 14978106]

29 **Kurihara Y**, Furue M. Interferon-γ enhances phorbol myristate acetate-induced cell attachment and tumor necrosis factor production via the NF-κB pathway in THP-1 human monocytic cells. *Mol Med Rep* 2013; **7**: 1739-1744 [PMID: 23589028 DOI: 10.3892/mmr.2013.1419]

30 **Pourshafie MR**, Sonnenfeld G. Treatment of an infected murine macrophage cell line (J774A.1) with interferon-gamma but not tumor necrosis factor-alpha or live Mycobacterium intracellulare alone modulates the expression of adhesion molecules. *J Interferon Cytokine Res* 1997; **17**: 69-75 [PMID: 9058312]

31 **Tong Q**, Vassilieva EV, Ivanov AI, Wang Z, Brown GT, Parkos CA, Nusrat A. Interferon-gamma inhibits T84 epithelial cell migration by redirecting transcytosis of beta1 integrin from the migrating leading edge. *J Immunol* 2005; **175**: 4030-4038 [PMID: 16148152]

32 **Utech M**, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, Parkos CA, Nusrat A. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. *Mol Biol Cell* 2005; **16**: 5040-5052 [PMID: 16055505 DOI: 10.1091/mbc.E05-03-0193]

33 **Günzel D**, Florian P, Richter JF, Troeger H, Schulzke JD, Fromm M, Gitter AH. Restitution of single-cell defects in the mouse colon epithelium differs from that of cultured cells. *Am J Physiol Regul Integr Comp Physiol* 2006; **290**: R1496-R1507 [PMID: 16397094 DOI: 10.1152/ajpregu.00470.2005]

34 **Adams RB**, Planchon SM, Roche JK. IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding. *J Immunol* 1993; **150**: 2356-2363 [PMID: 8450217]

35 **Bilsborough J**, Viney JL. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. *Gastroenterology* 2004; **127**: 300-309 [PMID: 15236195]

36 **Niess JH**, Reinecker HC. Lamina propria dendritic cells in the physiology and pathology of the gastrointestinal tract. *Curr Opin Gastroenterol* 2005; **21**: 687-691 [PMID: 16220046]

37 **Ausiello CM**, Cerquetti M, Fedele G, Spensieri F, Palazzo R, Nasso M, Frezza S, Mastrantonio P. Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. *Microbes Infect* 2006; **8**: 2640-2646 [PMID: 16935543 DOI: 10.1016/j.micinf.2006.07.009]

38 **Lee JY**, Kim H, Cha MY, Park HG, Kim YJ, Kim IY, Kim JM. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway. *J Mol Med* (Berl) 2009; **87**: 169-180 [PMID: 18985311 DOI: 10.1007/s00109-008-0415-2]

39 **Smith CL**, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. *Nutr Cancer* 2008; **60**: 757-767 [PMID: 19005975 DOI: 10.1080/01635580802192841]

40 **Lawley TD**, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. *PLoS Pathog* 2012; **8**: e1002995 [PMID: 23133377 DOI: 10.1371/journal.ppat.1002995]

41 **Yun B,** Oh S, Griffiths MW. Lactobacillus acidophilus modulates the virulence of Clostridium difficile. *J Dairy Sci* 2014; [Epub ahead of print] [PMID: 24856984 DOI: 10.3168/jds.2014-7921]

**P-Reviewer: Howarth GS, Matsuda A, Sadik R S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Figure 1 *Clostridium difficile*-induced colitis mouse model.** A: Wild type (WT) and interleukin 10-deficient (IL-10-/-) mice were pre-treated with an antibiotic cocktail for three days followed by an i.p. injection of clindamycin two days later, before being challenged with an oral administration of *C. difficile* (cfu, colony forming units); B: The mice were divided into four groups (*n* = 10 each): a control and *C. difficile* challenge group each for WT and IL-10-/- mice. The control groups underwent all pretreatment processes in parallel with the *C. difficile* challenge groups, but were not administered *C. difficile*.

![C:\Documents and Settings\Administrator\Application Data\Tencent\Users\409881474\QQ\WinTemp\RichOle\{0H6@3Z]OOVIHPSSGVYLRNI.jpg]()

**Figure 2 Cytokine expression in bone marrow-derived dendritic cells after *Clostridium difficile* toxin A stimulation.** The expression levels of interferon (IFN)-γ, interleukin (IL)-12 and IL-23 mRNAs were examined in BMDCs obtained from wild type (WT) and IL-10-deficient (IL-10-/-) mice. Error bars indicate standard error of the mean; a*P <* 0.05 *vs* WT.



**Figure 3 Body weight changes following *Clostridium difficile* challenge.** *C. difficile* challenge induced a reduction in body weight that was greater in interleukin 10-deficient (IL-10-/-) compared to wild type (WT) mice. Error bars indicate standard error of the mean.



**Figure 4 Histopathologic examination of the colonic tissue (× 100).** Hematoxylin and eosin staining of colon tissues from A: Wild type (WT); B: WT challenged with *C. difficile*; C: Interleukin 10-deficient (IL-10-/-); and D: IL-10-/- challenged with *C. difficile*; E: Quantification of colitis severity. Error bars indicate standard error of the mean; a*P <* 0.05 *vs* untreated.











E

**Figure 5 Cytokine expression in *Clostridium difficile* colitis.** The expression of interferon (IFN)-γ, interleukin (IL)-12, and IL-23 mRNAs in colonic tissues from A: Wild type (WT) control and *C. difficile*-challenged mice; B: IL-10-deficient (IL-10-/-) control and *C. difficile*-challenged mice; C: Cytokine expression in the colonic tissues of WT and IL-10-/- mice after induction of *C. difficile* colitis. Error bars indicate standard error of the mean; a*P <* 0.05 *vs* untreated; c*P* < 0.05 *vs* WT.



**A**



**B**



**C**

**Table 1 Primer sequences**

|  |  |  |
| --- | --- | --- |
| **RNA species** |  | **Oligonucleotides, 5'->3'** |
| IFN-γ | Sense | TGCATCTTGGCTTTGCAGCTCTTC |
| Antisense | GGGTTGTTGACCTCAAACTTGGCA |
| IL-12p40 | Sense | GGAAGCACGGCAGCAGAATA |
| Antisense | AACTTGAGGGAGAAGTAGGAATGG |
| IL-23p19 | Sense | AGCGGGACATATGAATCTACTAAGAGA |
| Antisense | GTCCTAGTAGGGAGGTGTGAAGTTG |

IFN: Interferon; IL: Interleukin.